Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054428
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 4
---
 THE COMPANY OR ANY OTHER PERSON.
NEITHER THE DELIVERY OF THIS REOFFER PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT
THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS REOFFER PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION
IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL
TO MAKE SUCH OFFER OR SOLICITATION.

<div align='center'>i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Some of the statements made under “Prospectus Summary,”
“Risk Factors,” and elsewhere in this reoffer prospectus, as well as the documents incorporated by reference herein, including
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, constitute forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,”
“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,”
“intends,” or “continue,” or the negative of these terms or other comparable terminology.

These forward-looking statements may include, but are not limited to,
statements related to our expected business, new product introductions, results of clinical studies, expectations regarding regulatory
clearance and the timing of U.S. Food and Drug Administration (“FDA”) or non-U.S. filings or approvals including meetings
with FDA or non-U.S. regulatory bodies, our ability to raise funds for general corporate purposes and operations, including our research
activities and clinical trials, procedures and procedure adoption, future results of operations, future financial position, our ability
to generate revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, the effect
of recent accounting pronouncements, our anticipated cash flows, our ability to finance operations from cash flows or otherwise, and statements
based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and intend to